- Adjuvant Pertuzumab and Herceptin in Initial Therapy in patients with HER2-positive early breast cancer
- Jose Baselga, MD, PhD., Physician-in-Chief and Chief Medical Officer, Memorial Hospital, MSKCC
- Sandra Horning, M.D., Chief Medical Officer and Head Global Product Development
- Ira Mellman, gRED: Ph.D., Vice President, Cancer Immunology, Genentech
- William Pao, pRED: M.D., Ph.D., Global Head Oncology Discovery and Translational Area, Roche
- Daniel O’Day, CEO Roche Pharmaceuticals